IMJUDO carries significant risks of immune-mediated and infusion-related adverse reactions, requiring vigilant monitoring and management.

Key Safety Precautions and Monitoring for IMJUDO Therapy

IMJUDO, particularly in combination with durvalumab, can induce severe or fatal immune-mediated adverse reactions affecting multiple organ systems, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, and pancreatitis. Early identification and prompt management are critical, with regular monitoring of liver enzymes, renal function, and endocrine parameters before each dose. Infusion-related reactions may also occur, necessitating interruption or discontinuation based on severity. IMJUDO is contraindicated in pregnancy due to embryo-fetal toxicity, and breastfeeding is not recommended during and for three months after therapy. Use in pediatric patients is not specified in the description.